Kim Jung Young, Peters Katherine B, Herndon James E, Affronti Mary Lou
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
J Adv Pract Oncol. 2020 Sep-Oct;11(7):684-692. doi: 10.6004/jadpro.2020.11.7.3. Epub 2020 Sep 1.
Patients with glioblastoma have poor overall survival and experience significant burden from neurologic decline and adverse treatment effects. Despite the well-known benefits of early palliative care integration with oncology care, utilization of palliative care is low. The purpose of this quality improvement (QI) project is to investigate the feasibility, value, and effectiveness of using an adapted palliative care screening tool to improve outpatient palliative care screening and referral of glioblastoma patients. This QI project was conducted over a 10-week period. A glioma palliative care screening tool was developed and integrated into outpatient visits. Providers were required to use the screening tool during each patient visit. Patients 18 years or older who were diagnosed with a World Health Organization grade IV glioma and returning to the neuro-oncology clinic for a brain MRI evaluation were targeted. Screening, palliative care discussion, and referral rates were evaluated. Among 530 eligible patients who returned to the clinic over a 10-week period, the tool was available for 433 patients. Fifty-six percent (n = 294/530) of the patients were screened. Nine percent (n = 27) of screened patients were identified as candidates for a palliative care referral (score ≥ 5 on the screening tool). Of these 27 patients, the proportion of patients who had a palliative care discussion was 63% (n = 17). Overall, 71% (n = 12) of patients who had a palliative care discussion were referred to a palliative care provider. Integrating a glioma palliative care screening tool with outpatient visits can draw attention to palliative care needs and lead to a referral to palliative care.
胶质母细胞瘤患者的总体生存率较低,且因神经功能衰退和不良治疗效果而承受巨大负担。尽管早期姑息治疗与肿瘤治疗相结合具有众所周知的益处,但姑息治疗的利用率却很低。本质量改进(QI)项目的目的是研究使用一种经过改良的姑息治疗筛查工具来改善胶质母细胞瘤患者门诊姑息治疗筛查和转诊的可行性、价值和有效性。该QI项目为期10周。开发了一种胶质瘤姑息治疗筛查工具并将其纳入门诊就诊流程。要求医护人员在每次患者就诊时使用该筛查工具。目标人群为年龄在18岁及以上、被诊断为世界卫生组织IV级胶质瘤且返回神经肿瘤门诊进行脑部MRI评估的患者。对筛查、姑息治疗讨论及转诊率进行了评估。在10周内返回门诊的530名符合条件的患者中,有433名患者能够使用该工具。56%(n = 294/530)的患者接受了筛查。9%(n = 27)的筛查患者被确定为姑息治疗转诊候选人(筛查工具得分≥5分)。在这27名患者中,进行了姑息治疗讨论的患者比例为63%(n = 17)。总体而言,进行了姑息治疗讨论的患者中有71%(n = 12)被转诊至姑息治疗机构。将胶质瘤姑息治疗筛查工具与门诊就诊相结合,可以使人们关注姑息治疗需求,并促成向姑息治疗机构的转诊。